Explore Annogen’s News
Corteva Annogen collaborating on functional annotation to accelerate crop improvement
New collaboration in crop engineering Collaborating on functional annotation to accelerate crop improvement Corteva Agriscience™ and Annogen B.V. are working together to functionally annotate thousands of expression elements in maize. Leveraging Annogen's innovative...
Annogen invited to speak at CropIB 2025
We’re thrilled to share that our Founder & CEO, Joris van Arensbergen, has been invited to speak at the prestigious Crop Innovation and Business (CIB) Conference in Cologne, taking place from 30 March – 1 April 2025. Joris will be delivering a talk on Large-scale...
UCSF, Annogen Announce Collaboration to Identify Superior Treg-Specific Promoters
UCSF, Annogen Announce Collaboration to Identify Superior Treg-Specific Promoters Annogen, a leader in gene expression engineering, and the prestigious labs of Qizhi Tang and Brian Shy at University of California, San Francisco (UCSF) today announced a collaboration...
Annogen to perform functional genome annotations for KWS to accelerate crop improvement
Einbeck, Germany; Amsterdam, The Netherlands December 5, 2024 KWS SAAT SE & Co. KGaA and Annogen B.V. today announced a partnership in which Annogen will use its FACE™ platform to functionally annotate non-coding variants that are of interest to KWS. FACE™ is an...
Novel Genetic Switches Make Gene Therapies Safer and More Effective -Financieel Dagblad Interview (Nov 2024)
Article as featured in the Financieel Dagblad (Financial Times), 29 November 2024 (link)
Annogen – KeyGene collaboration demonstrates efficacy of the SuRE™ platform to identify gain-of-function in new variants of crops
KeyGene collaboration demonstrates efficacy of the SuRE™ platform to identify gain-of-function in new variants of crops.
Annogen Announces Research Collaboration with Orchard Therapeutics for the Development of CNS-cell Specific Promoters
Annogen today announced a research collaboration with Orchard Therapeutics, a global gene therapy leader, for the identification of immune cell-specific human promoters for use in certain pre-clinical hematopoietic stem cell (HSC) gene therapy programs.
Annogen signs deal in which SuRE™ libraries are used for In-Vivo Capsid screening
Updates - December 2023 Annogen has signed a deal with an undisclosed gene therapy company for an AAV capsid screening project. For this project, Annogen will deliver its SuRE™ barcoding platform and downstream bioinformatics analysis to track tissue-specific biases...
Annogen introduces HEK293-INDX1™ – a clonal HEK293 cell line for inducible expression of toxic proteins such as Rep during AAV production
Updates - October 2023 Annogen is excited to share our latest break through in cellular engineering. We've successfully combined our SuRE™ promoter screening platform and our AIM™ integration site screening platform to establish HEK293 clones with near-zero baseline...
